eShowcase: TrialSpace Designer
Tools for Clinical Trials Professionals
Package integrates smoothly into existing business enterprise software formats
Fast Track Systems Inc. (Conshohocken, PA) has a new enterprise solution for advancing the clinical development process. According to Fast Track Systems, TrialSpace Designer improves quality by ensuring protocol consistency and accuracy, and eliminates operational ambiguities at the trial design stage.
The solution is tailored to a life science company's specific therapeutic areas to adhere to individual corporate processes, SOPs, and standard text, plus it incorporates existing Word templates. With TrialSpace Designer, clinical trial professionals have access to indication-specific industry benchmark data on procedures and costs from the company's proprietary databases. Fast Track Systems says that the package delivers better operational efficiency with faster trial startup and completion and reduces avoidable operational costs. Among other benefits are quicker and cleaner trial summations for regulatory submissions and shorter trial timelines.
TrialSpace Designer
Fast Track Systems Inc., (215) 358-1400, www.fast-track.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
